Stroke-Associated Letal Outcome with Hympavzi: Michael Makris on Pfizer’s Announcement
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”Important.
Pfizer has just announced that a person with hemophilia, in their marstacimab (Hympavzi) clinical trial program, has died from a thrombotic stroke.
I attach the letter they sent to a number of patient organisations including the World Federation of Hemophilia.
The information provided in the letter is minimal.
I hope they reach out to all hemophilia doctors worldwide who can potentially prescribe this drug to inform them about this event, and the other thrombotic event in the same clinical trial that was previously disclosed at the EAHAD and ISTH meetings.
The patient who died, had hemophilia A with an inhibitor.
Marstacimab is at present only approved for persons with hemophilia A and B without an inhibitor.”
Stay updated with Hemostasis Today.
-
Apr 12, 2026, 22:12Maciej Banach: The ‘Metastatic’ Cardiovascular Threat We Can No Longer Ignore
-
Apr 12, 2026, 21:52Umar Jawed: The Most Dangerous Anti-D Result Is Not the Highest One – It’s the One You Underestimate Early
-
Apr 12, 2026, 21:37Demosthenes Panagiotakos: Hellenic Atherosclerosis Society Calls for Papers on Innovative Strategies in Atherosclerotic Plaque Management
-
Apr 12, 2026, 21:24Heghine Khachatryan: Diagnosing PNH in Resource-Limited Settings
-
Apr 12, 2026, 21:15Katariina Öörni: Role of Cholesterol Absorption Efficiency in Atherosclerosis
-
Apr 12, 2026, 17:34Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow
-
Apr 12, 2026, 17:33Augustina Isioma Ikusemoro: ABO Typing Is Not the Same in Infants and Adults
-
Apr 12, 2026, 17:32Bastu Odoka: Same Blood Group Does Not Guarantee Compatibility
-
Apr 12, 2026, 17:31Jack Hadfield: SARS-CoV-2–Associated Lasting Mitochondrial Injury in Cardiomyocytes